ClinicalTrials.gg
Not yet recruitingNCT07807917Updated Sep 30, 2026

Quality of Life After Lower Respiratory Tract Infection

An observational study in Lower Respiratory Tract Infection (LRTI), Chest Infection and Quality of Life, sponsored by University of Nottingham. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Nottingham · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

Lower respiratory tract infections (LRTIs) are any infections below the vocal cords which affect the airways or the air sacs in the lungs. They include pneumonia, bronchitis and chest infections and are usually caused by viruses such as influenza, COVID-19 or Respiratory Syncytial Virus (RSV), or by bacteria such as pneumococcus. LRTIs are common, particularly in older adults; in the UK approximately 15% of people aged over 65 years will experience a chest infection each year and many of those will need in-patient treatment.

People who have had a chest infection may experience slow recovery after their infection. Patients often report that their quality of life is worse after an infection (for example persistent fatigue, reduced physical functioning, and mental health challenges) and this can affect the return to usual activities. However, there have not been many studies that have looked at how the quality of life changes in the months following a chest infection, and why some people take longer to recover.

In this study, the investigators will use a well-recognised questionnaire to measure quality of life for up to one year in adults who have been admitted to hospital with a chest infection. The findings will help the investigators to assess how long-term quality of life is affected after a chest infection and what factors may affect it. The results will also permit calculation of the costs faced by patients during recovery from a chest infection, in financial terms. These results will feed into studies looking at ways of improving recovery after a chest infection.

Read the detailed description

Acute lower respiratory tract infections (LRTIs) are a group of infections affecting the respiratory tract below the level of the larynx, including pneumonia, acute bronchitis, bronchiolitis, acute infective exacerbations of chronic obstructive pulmonary disease (COPD).

In those who survive their initial episode of LRTI, recovery may be slow with adverse outcomes which may last months or even years after the initial episode and have implications for patients, their families and health care resources. A recent prospective cohort study in the U.S. (PNEUMO) reported that at 6 months after hospitalisation with community-acquired pneumonia (CAP) and compared to their pre-hospitalisation status, 12.8% of participants had lost the ability to perform at least one basic activity of daily living (ADL), 22.0% lost the ability to perform at least one instrumental ADL, 41.6% suffered cognitive impairment, 58.7% had loss of employment, and 23.6% had decreased quality of life (Han et al 2025). Additionally pneumonia patients have high rates of readmission to hospital, which in turn is associated with significant inpatient mortality (Lawrence et al 2023), high rates of primary care consultation within 7 days of discharge (Baskaran et al 2021), increased risk of cardiovascular events and heart failure (Eurich et al 2017; Violi et al 2017), recurrent pneumonia (Baskaran et al 2022) and persistent symptoms (Pick et al 2019).

LRTIs therefore heavily impact patients, their families and carers, and the use of healthcare resources. Measuring the quality of life in patients hospitalised with acute LRTIs for up to one year after their discharge is an important component in the broader assessment of the cost of LRTIs in the UK, but long-term quality of life data in these patients are limited.

Every individual's experience of recovery from pneumonia is unique reflecting the complex interplay between their clinical characteristics, existing co-morbidities, frailty, physical and mental status, illness severity, and underlying causative micro-organism. There are few long-term data on outcomes which are important to patients following an episode of LRTI, including patient-perceived quality of life. It is therefore important to study this outcome and to identify those factors which may be associated with quality-of life measures in order to: a) gain a broader picture of the impact of LRTI on patients themselves; b) inform future trials assessing interventions aimed at improving patients' quality of life; c) to feed into analyses of the health economic costs of LRTIs.

The purpose of this study is to gain a better understanding of how health-related quality of life is affected in people who are hospitalised after a LRTI. The primary objective is to document health states and utility indexes for hospitalised LRTI patients and their evolution over the course of one year after the initial episode. The secondary objective is to evaluate associations between patient characteristics and their hospital stay with their health-related quality of life.

Participants will be recruited when they are almost ready to be sent home from hospital. Informed consent will be obtained prior to participation (or for those lacking capacity to provide consent, a consultee acting on their behalf will complete a declaration form). Before discharge participants will be asked to complete the EQ-5D-5L health-related quality of life questionnaire . After discharge from hospital, participants will complete the same questionnaire at one month, three months, six months and one year after discharge. Questionnaires will be administered by telephone, digitally (email form) or by post.

Descriptive statistics will be conducted at each time point (discharge, 1, 3, 6, 12 months):

  1. EQ-5D-5L profiles: Number and proportion at each level (1-5) for each dimension.
  2. Ceiling/floor effects: Proportion at ceiling (11111) and floor (severe problems on ≥3 dimensions) reported at each timepoint.
  3. Utility values: Mean, Standard Deviation (SD), Standard Error (SE), median, Interquartile Range (IQR), min, max, and n.
  4. VAS scores: Mean, SD, median, IQR, min, max (descriptive only).
  5. Change scores: Mean change from baseline to each follow-up, with 95% Confidence Interval (CI).
  6. Population comparison: Utility decrement from age-sex matched norms at each time point.

Quality-Adjusted Life Years (QALYs) will be calculated using area-under-the-curve with trapezoidal rule and linear interpolation:

  1. Time zero: Hospital discharge date.
  2. Intervals: Discharge→1 month, 1→3 months, 3→6 months, 6→12 months. Actual days used.
  3. Formula: QALY per interval = [(Ustart + Uend) / 2] × time in years. Total QALYs =

    • (QALY_intervals)
  4. Mortality: Deaths contribute QALYs to date of death (utility = 0 thereafter).
  5. QALY loss: Calculated as the difference between expected and observed QALYs over 12 months. Expected QALYs derived from age-sex matched English population norms using adjusted limited dependent variable mixture models (ALDVMM) with EQ-5D-5L responses mapped to 3L using Hernández Alava algorithm.

Health state utility values reported by severity tier and time point will serve as inputs for cost-effectiveness models, where survival is incorporated through model structure using transition probabilities derived from the linked CPRD-HES cohort.

All cohorts will be stratified by age, sex, severity tier, diagnostic category, index of Multiple Deprivation quintile, number of co-morbidities, ECOG Performance Status, CURB-65 score.

To model utility trajectories over time and identify predictors of recovery, the investigators will use mixed-effects linear regression with random intercepts. Fixed effects: time, age, sex, severity tier, performance status, comorbidity count. Time × severity interaction explored to assess differential recovery rates. Predicted 12-month utilities derived from model.

Because EQ-5D utility values have an upper limit and many patients may report full health at follow-up, the investigators will check whether the model fits the data and produces realistic predicted values. If predictions fall outside the valid range or the model performs poorly, alternative approaches (such as Tobit regression, generalised linear models with clustered responses, or two-part models) will be explored in sensitivity analyses.

Missing data: Completion rates will be reported by timepoint and baseline characteristics compared between completers and non-completers. The following sensitivity analyses for missing data will be performed (a) multiple imputation by chained equations (MICE) conditional on baseline characteristics and severity tier, with last observation carried forward (LOCF) as conservative comparator; (b) Complete case: restricted to participants with EQ-5D-5L data at all five timepoints.

02

Conditions studied

  • Lower Respiratory Tract Infection (LRTI)
  • Chest Infection
  • Quality of Life

Browse trials for

Keywords

  • Lower respiratory tract infection
  • Chest infection
  • Pneumonia
  • Quality of life
  • EQ-5D-5L
03

In context

Pneumonia

1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.

This study's planned enrollment of 200 is below the median of 252 across 535 observational studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from the adult respiratory wards at Nottingham City Hospital as the majority of patients with a primary diagnosis of lower respiratory tract infection are admitted to these wards.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18years (no upper age limit).
  • Treated by attending physician as lower respiratory tract infection/community-acquired pneumonia, regardless of microbiologically-confirmed pathogen.
  • Ability to give or appropriate consultee available to give advice.

Exclusion criteria

Exclusion Criteria:

  • Hospital admission within 14 days preceding the index admission
  • Post-obstructive pneumonia secondary to Lung Cancer
  • Patients treated for active Tuberculosis (TB)
  • Receiving palliative treatment only
  • Unable to understand written or spoken English
  • Presumed to be unable to answer the questionnaires over the follow-up period.
  • Exacerbations of chronic lung disease such as asthma, or bronchiectasis.
  • Previously enrolled in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lower respiratory tract infection

    Adults hospitalised with a lower respiratory tract infection (low, moderate or severe severity).

06

What researchers measure

Primary outcomes

  1. Change from baseline in health state utility values over one year

    Health state utility values calculated from EQ-5D-5L profiles using preference-based value sets pre-discharge and at 1, 3, 6 and 12 months post-discharge.

    Time frame: From enrolment to one year post-discharge from hospital

07

Study locations

1 site
08

References and documents

Publications

  • Pick HJ, Bolton CE, Lim WS, McKeever TM. Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review. Eur Respir J. 2019 Mar 18;53(3):1802165. doi: 10.1183/13993003.02165-2018. Print 2019 Mar. PubMed 30635298 ↗
  • Baskaran V, Lim WS, McKeever TM. Effects of tobacco smoking on recurrent hospitalisation with pneumonia: a population-based cohort study. Thorax. 2022 Jan;77(1):82-85. doi: 10.1136/thoraxjnl-2020-216494. Epub 2021 Jun 18. PubMed 34145048 ↗
  • Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, Nozzoli C, Venditti M, Chirinos JA, Corrales-Medina VF; SIXTUS (Thrombosis-Related Extrapulmonary Outcomes in Pneumonia) Study Group. Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia. Clin Infect Dis. 2017 Jun 1;64(11):1486-1493. doi: 10.1093/cid/cix164. PubMed 28205683 ↗
  • Baskaran V, Pearce F, Harwood RH, McKeever TM, Lim WS. Primary care consultations after hospitalisation for pneumonia: a large population-based cohort study. Br J Gen Pract. 2021 Mar 26;71(705):e250-e257. doi: 10.3399/BJGP.2020.0890. Print 2021 Apr. PubMed 33753348 ↗
  • Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up. BMJ. 2017 Feb 13;356:j413. doi: 10.1136/bmj.j413. PubMed 28193610 ↗
  • Lawrence H, McKeever TM, Lim WS; British Thoracic Society. Readmission following hospital admission for community-acquired pneumonia in England. Thorax. 2023 Dec;78(12):1254-1261. doi: 10.1136/thorax-2022-219925. Epub 2023 Jul 31. PubMed 37524392 ↗
  • Han JH, Resser JJ, Baughman A, Grijalva CG, Johnson J, Miller KF, Roberts CS, Johnson KD, Weiss T, Self WH; PNEUMO Study Investigators. Community-acquired pneumonia in hospitalized adults: long-term morbidities and their risk factors. BMC Infect Dis. 2025 Jul 1;25(1):826. doi: 10.1186/s12879-025-11186-w. PubMed 40597744 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: description
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07807917
Responsible party
Sponsor
First posted
Sep 8, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Professor Tricia McKeever
Contact
tricia.mckeever@nottingham.ac.uk
+44 (0)115 8231721
Jhon Galindo-Rodriguez
Contact
Jhon.Galindo-Rodriguez@nottingham.ac.uk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion